Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5005119 | 0.89 | NOS3 (0.61) | NOS3NOS2 | |
| SCHEMBL251337 | 0.86 | NOS3 (1.00) | NOS3NOS2 | |
| SCHEMBL8234434 | 0.86 | NOS3 (0.60) | NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL8097464 | 0.85 | NOS3 (0.97) | NOS3NOS2 | |
| SCHEMBL8063313 | 0.83 | NOS3 (0.72) | NOS3NOS2 | |
| SCHEMBL8060901 | 0.83 | NOS3 (1.00) | NOS3NOS2 | |
| SCHEMBL8056702 | 0.83 | NOS3 (0.71) | NOS3NOS2 | |
| SCHEMBL5005082 | 0.83 | NOS3 (0.71) | NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL8099807 | 0.82 | NOS3 (0.70) | NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL8099002 | 0.82 | NOS3 (0.97) | NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| WO-2007058583-A2 | NOVEL 2-AMINO-HETEROCYCLES USEFUL IN THE TREATMENT OF ABETA-RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | PSEN2, APP, PSEN1 | NOS3 2189/4885NOS2 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.